Changes in Neutrophil–Lymphocyte or Platelet–Lymphocyte Ratios and Their Associations with Clinical Outcomes in Idiopathic Pulmonary Fibrosis
Identification of prognostic and predictive biomarkers in idiopathic pulmonary fibrosis (IPF) could aid assessment of disease severity and prediction of progression and response to treatment. This analysis examined reference ranges for neutrophil–lymphocyte ratio (NLR) and platelet–lymphocyte ratio...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-04-01
|
| Series: | Journal of Clinical Medicine |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2077-0383/10/7/1427 |
| _version_ | 1797539154890850304 |
|---|---|
| author | Steven D. Nathan Jayesh Mehta John Stauffer Elizabeth Morgenthien Ming Yang Susan L. Limb Sangeeta Bhorade |
| author_facet | Steven D. Nathan Jayesh Mehta John Stauffer Elizabeth Morgenthien Ming Yang Susan L. Limb Sangeeta Bhorade |
| author_sort | Steven D. Nathan |
| collection | DOAJ |
| description | Identification of prognostic and predictive biomarkers in idiopathic pulmonary fibrosis (IPF) could aid assessment of disease severity and prediction of progression and response to treatment. This analysis examined reference ranges for neutrophil–lymphocyte ratio (NLR) and platelet–lymphocyte ratio (PLR) in IPF, and the relationship between NLR or PLR changes and clinical outcomes over 12 months. This post hoc analysis included patients with IPF from the Phase III, double-blind trials of pirfenidone, ASCEND (NCT01366209) and CAPACITY (NCT00287716 and NCT00287729). The relationship between change from baseline to Month 12 in NLR or PLR (divided into quartiles (Q1–Q4)) and outcomes (mortality, respiratory hospitalization, declines in lung function, exercise capacity and quality of life) was assessed. Estimated reference ranges at baseline for all patients analyzed (<i>n</i> = 1334) were 1.1–6.4 for NLR and 56.8–250.5 for PLR. Significant trends were observed across NLR and PLR quartiles for all outcomes in placebo-treated patients, with patients manifesting the greatest NLR or PLR changes experiencing the worst outcomes. These results suggest that the greatest NLR or PLR changes over 12 months were associated with worse clinical outcomes. Further research is needed to determine the utility of NLR and PLR as prognostic biomarkers in IPF. |
| first_indexed | 2024-03-10T12:41:12Z |
| format | Article |
| id | doaj.art-0fcef396202d4972bf736e665a76725a |
| institution | Directory Open Access Journal |
| issn | 2077-0383 |
| language | English |
| last_indexed | 2024-03-10T12:41:12Z |
| publishDate | 2021-04-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Clinical Medicine |
| spelling | doaj.art-0fcef396202d4972bf736e665a76725a2023-11-21T13:49:39ZengMDPI AGJournal of Clinical Medicine2077-03832021-04-01107142710.3390/jcm10071427Changes in Neutrophil–Lymphocyte or Platelet–Lymphocyte Ratios and Their Associations with Clinical Outcomes in Idiopathic Pulmonary FibrosisSteven D. Nathan0Jayesh Mehta1John Stauffer2Elizabeth Morgenthien3Ming Yang4Susan L. Limb5Sangeeta Bhorade6Advanced Lung Disease and Transplant Program, Inova Fairfax Hospital, 3300 Gallows Rd, Falls Church, VA 22042, USAFeinberg School of Medicine, Northwestern University, 420 E Superior St, Chicago, IL 60611, USAGenentech, Inc., 1 DNA Way, South San Francisco, CA 94080, USAGenentech, Inc., 1 DNA Way, South San Francisco, CA 94080, USAGenentech, Inc., 1 DNA Way, South San Francisco, CA 94080, USAGenentech, Inc., 1 DNA Way, South San Francisco, CA 94080, USAFeinberg School of Medicine, Northwestern University, 420 E Superior St, Chicago, IL 60611, USAIdentification of prognostic and predictive biomarkers in idiopathic pulmonary fibrosis (IPF) could aid assessment of disease severity and prediction of progression and response to treatment. This analysis examined reference ranges for neutrophil–lymphocyte ratio (NLR) and platelet–lymphocyte ratio (PLR) in IPF, and the relationship between NLR or PLR changes and clinical outcomes over 12 months. This post hoc analysis included patients with IPF from the Phase III, double-blind trials of pirfenidone, ASCEND (NCT01366209) and CAPACITY (NCT00287716 and NCT00287729). The relationship between change from baseline to Month 12 in NLR or PLR (divided into quartiles (Q1–Q4)) and outcomes (mortality, respiratory hospitalization, declines in lung function, exercise capacity and quality of life) was assessed. Estimated reference ranges at baseline for all patients analyzed (<i>n</i> = 1334) were 1.1–6.4 for NLR and 56.8–250.5 for PLR. Significant trends were observed across NLR and PLR quartiles for all outcomes in placebo-treated patients, with patients manifesting the greatest NLR or PLR changes experiencing the worst outcomes. These results suggest that the greatest NLR or PLR changes over 12 months were associated with worse clinical outcomes. Further research is needed to determine the utility of NLR and PLR as prognostic biomarkers in IPF.https://www.mdpi.com/2077-0383/10/7/1427NLRPLRidiopathic pulmonary fibrosisclinical outcomesbiomarker |
| spellingShingle | Steven D. Nathan Jayesh Mehta John Stauffer Elizabeth Morgenthien Ming Yang Susan L. Limb Sangeeta Bhorade Changes in Neutrophil–Lymphocyte or Platelet–Lymphocyte Ratios and Their Associations with Clinical Outcomes in Idiopathic Pulmonary Fibrosis Journal of Clinical Medicine NLR PLR idiopathic pulmonary fibrosis clinical outcomes biomarker |
| title | Changes in Neutrophil–Lymphocyte or Platelet–Lymphocyte Ratios and Their Associations with Clinical Outcomes in Idiopathic Pulmonary Fibrosis |
| title_full | Changes in Neutrophil–Lymphocyte or Platelet–Lymphocyte Ratios and Their Associations with Clinical Outcomes in Idiopathic Pulmonary Fibrosis |
| title_fullStr | Changes in Neutrophil–Lymphocyte or Platelet–Lymphocyte Ratios and Their Associations with Clinical Outcomes in Idiopathic Pulmonary Fibrosis |
| title_full_unstemmed | Changes in Neutrophil–Lymphocyte or Platelet–Lymphocyte Ratios and Their Associations with Clinical Outcomes in Idiopathic Pulmonary Fibrosis |
| title_short | Changes in Neutrophil–Lymphocyte or Platelet–Lymphocyte Ratios and Their Associations with Clinical Outcomes in Idiopathic Pulmonary Fibrosis |
| title_sort | changes in neutrophil lymphocyte or platelet lymphocyte ratios and their associations with clinical outcomes in idiopathic pulmonary fibrosis |
| topic | NLR PLR idiopathic pulmonary fibrosis clinical outcomes biomarker |
| url | https://www.mdpi.com/2077-0383/10/7/1427 |
| work_keys_str_mv | AT stevendnathan changesinneutrophillymphocyteorplateletlymphocyteratiosandtheirassociationswithclinicaloutcomesinidiopathicpulmonaryfibrosis AT jayeshmehta changesinneutrophillymphocyteorplateletlymphocyteratiosandtheirassociationswithclinicaloutcomesinidiopathicpulmonaryfibrosis AT johnstauffer changesinneutrophillymphocyteorplateletlymphocyteratiosandtheirassociationswithclinicaloutcomesinidiopathicpulmonaryfibrosis AT elizabethmorgenthien changesinneutrophillymphocyteorplateletlymphocyteratiosandtheirassociationswithclinicaloutcomesinidiopathicpulmonaryfibrosis AT mingyang changesinneutrophillymphocyteorplateletlymphocyteratiosandtheirassociationswithclinicaloutcomesinidiopathicpulmonaryfibrosis AT susanllimb changesinneutrophillymphocyteorplateletlymphocyteratiosandtheirassociationswithclinicaloutcomesinidiopathicpulmonaryfibrosis AT sangeetabhorade changesinneutrophillymphocyteorplateletlymphocyteratiosandtheirassociationswithclinicaloutcomesinidiopathicpulmonaryfibrosis |